TY - JOUR
T1 - Clinical trials for progressive differentiated thyroid cancer
T2 - Patient selection, study design, and recent advances
AU - Schlumberger, Martin
AU - Sherman, Steven I.
N1 - Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2009/12/1
Y1 - 2009/12/1
N2 - Treatment of metastatic differentiated thyroid cancer is first based on the use of radioiodine and thyrotropin-suppressive thyroid hormone treatment. The recent availability of molecular-targeted therapies has lead to reconsideration of the treatment strategy in differentiated thyroid cancer patients with distant metastases who are resistant to radioiodine therapy. In those with progressive disease, treatment with kinase inhibitors should be offered preferably in the context of a prospective trial.
AB - Treatment of metastatic differentiated thyroid cancer is first based on the use of radioiodine and thyrotropin-suppressive thyroid hormone treatment. The recent availability of molecular-targeted therapies has lead to reconsideration of the treatment strategy in differentiated thyroid cancer patients with distant metastases who are resistant to radioiodine therapy. In those with progressive disease, treatment with kinase inhibitors should be offered preferably in the context of a prospective trial.
UR - http://www.scopus.com/inward/record.url?scp=75449115904&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=75449115904&partnerID=8YFLogxK
U2 - 10.1089/thy.2009.1603
DO - 10.1089/thy.2009.1603
M3 - Review article
C2 - 20001721
AN - SCOPUS:75449115904
SN - 1050-7256
VL - 19
SP - 1393
EP - 1400
JO - Thyroid
JF - Thyroid
IS - 12
ER -